Skip to main content
SpringerLink
Log in

Pioglitazone oder Sulfonylharnstoffe als Add-on-Therapie zu Metformin

Pioglitazone or sulfonylureas as add-on therapy to metformin

  • Journal Club
  • Published:
Der Diabetologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005–2012

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endokrinologie, Diabetologie und klinische Ernährung, Medizinische Klinik, Kantonsspital Münsterlingen, Spitalcampus 1, 8596, Münsterlingen, Schweiz

    V. Pavlicek

Authors
  1. V. Pavlicek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Pavlicek.

Ethics declarations

Interessenkonflikt

V. Pavlicek gibt folgende Interessenkonflikte an: Advisory Boards für MSD, Sanofi Aventis, Novo Nordisk, AstraZeneca, Boehringer Ingelheim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pavlicek, V. Pioglitazone oder Sulfonylharnstoffe als Add-on-Therapie zu Metformin. Diabetologe 14, 101–103 (2018). https://doi.org/10.1007/s11428-018-0313-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-018-0313-3

Search

Navigation